Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 2, 2026Therapeutic Advances in HematologyOpen Access

Real-world efficacy and tolerability of ixazomib-based combination therapies in advanced multiple myeloma and other plasma cell neoplasms

View Full Paper
Ask AI
Bookmark
Share

Authors

XZXiang ZhouJMJulia MersiCRChristine Riedhammer

Discussion

Loading...

Member takes

Overview

Retrospective analysis finds ixazomib therapies effective in multiple myeloma, indicating better outcomes with less pretreatment.

Key Points

  • The aim is to analyze the efficacy and tolerability of ixazomib-based combination therapies in patients with advanced multiple myeloma and plasma cell neoplasms.
  • Single-center retrospective analysis of 126 patients
  • Assessment of overall response rate (ORR)
  • Evaluation of progression-free survival (PFS) and overall survival (OS)
  • Multivariate analysis for survival factors
  • Overall response rate (ORR) was 52.5%
  • Triple-class refractory patients had a significantly lower ORR (10.5%) compared to non-refractory (60.2%)
  • Median progression-free survival (PFS) was 7.9 months
  • Median overall survival (OS) was 84.1 months
  • Grade ⩾3 hematologic adverse events occurred in 15.1% of patients

Cite This Study

Zhou et al. (2026) studied this question.

synapsesocial.com/papers/69a52e64f1e85e5c73bf20dchttps://doi.org/10.1177/20406207261421841
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Enhancing Multiple Myeloma Treatment Outcomes with Ixazomib: Insights and Perspectives2024
  2. 2Treatment outcomes in patients with newly diagnosed multiple myeloma receiving ixazomib as initial therapy: A retrospective, observational, real-world historical database analysis from China2025
  3. 3Real-world efficacy and safety of ixazomib maintenance therapy in Chinese patients with newly diagnosed multiple myeloma: A multicenter retrospective study2025
  4. 4Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma2024 · 8 citations
  5. 5An open-label rollover study to assess the long-term safety of ixazomib2025